Vosilasarm
Also known as: RAD-140, RAD140, Testolone, EP0062
Classification
Sarm
Regulatory Status
not-established
Overview
Vosilasarm (RAD-140, testolone) is a non-steroidal oral SARM that acts as an androgen receptor agonist; an investigational oncology program (EP0062) evaluates AR agonism in AR+/ER+ breast cancer, distinct from bodybuilding marketing.
Evidence and limitations
Human/preclinical evidence breakdown is not available in this record.
Pathways
Benefits
INN vosilasarm refers to RAD-140; early-phase oncology studies exist, but no FDA-approved indication, and bodybuilding uses are unapproved with hepatotoxicity case reports.
Interactions & cautions
Drug interactions
other androgens, anabolic steroids, or SARMs — Additive androgenic and hepatotoxicity concerns (review)
hepatotoxic drugs or supplements — May worsen DILI risk (review)
These are observational flags for review, not individualized instructions.
Sources
Educational reference only — not medical advice.